Markets

Galena Biopharma (GALE) Catches Eye: Stock Moves Up 15.1%

Galena Biopharma, Inc.GALE was a big mover last session, as its shares rose over 15% on the day. The upside was driven by the announcement that the company's Phase 3, PRESENT clinical trial on NeuVax™ (nelipepimut-S) has achieved 70th qualifying disease free survival (DFS) event. This also led to far more shares changing hands than in a normal session. Yesterday's rally breaks the trend for the company, as the stock is now trading above the volatile price range of $0.80 to $1.15 in the past one-month time frame.

Over the last 30 days, the company witnessed one positive and two negative estimate revisions. Meanwhile, the Zacks Consensus Estimate moved higher, suggesting solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.

Galena Biopharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked biomedical stock is Anika Therapeutics Inc. ANIK with a Zacks Rank #1 (Strong Buy).

Is GALE going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

GALENA BIOPHARM (GALE): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ANIK

Other Topics

Investing Stocks

Latest Markets Videos